REGENTIS BIOMATERIALS LTD. Initial Statement of Beneficial Ownership

REGENTIS BIOMATERIALS LTD. director Ben-Elazar Pini reported his initial ownership position in a Form 3 filing.

Accepted by SEC EDGAR 03/18/2026 - 04:30 PM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. director Ben-Elazar Pini reported his initial ownership position in a Form 3 filing. He holds employee stock options covering 39,295 shares of common stock at an exercise price of $0.01 per share, fully vested and expiring on January 23, 2035.

He also holds warrants to purchase 15,831 ordinary shares of common stock at an exercise price of $5.00 per share, which are currently exercisable and have a three-year term, expiring on December 5, 2028. In addition, he directly owns 128,666 ordinary shares with no par value per share. The filing reflects holdings only and does not report new purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ben-Elazar Pini

Role Director

Type	Security	Shares	Price	Value
Holding	Employee Stock Option (Right to Buy)	--	--	--
Holding	Warrants to purchase ordinary shares	--	--	--
Holding	Ordinary Shares, no par value per share	--	--	--

Holdings: Employee Stock Option (Right to Buy) — 39,295 contracts (Direct); Warrants to purchase ordinary shares — 15,831 contracts (Direct); Ordinary Shares, no par value per share — 128,666 shares (Direct)

Footnotes (2)

F1. This option grant is fully vested as of this date.
F2. The warrants are currently exercisable and have a three year term.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider holdings did Ben-Elazar Pini report in RGNT on this Form 3?

He reported direct ownership of 128,666 ordinary shares. He also listed fully vested stock options over 39,295 common shares and currently exercisable warrants over 15,831 common shares, establishing his initial disclosed equity position in REGENTIS BIOMATERIALS LTD.

What stock options does Ben-Elazar Pini hold in REGENTIS BIOMATERIALS (RGNT)?

He holds employee stock options for 39,295 common shares at an exercise price of $0.01 per share. These options are fully vested as of the reported date and expire on January 23, 2035, providing long-dated, low-cost upside exposure.

What warrant position did Ben-Elazar Pini disclose in RGNT?

He disclosed warrants to purchase 15,831 ordinary shares of common stock at an exercise price of $5.00 per share. The warrants are currently exercisable, have a three-year term, and are scheduled to expire on December 5, 2028, according to the filing footnote.

Does this RGNT Form 3 show any insider buying or selling activity?

No, the Form 3 lists holdings only and shows no buy or sell transactions. All three entries are categorized as holdings, with unknown transaction codes and no transaction shares, indicating an initial ownership report rather than recent trading activity.

Is Ben-Elazar Pini a director or officer of REGENTIS BIOMATERIALS LTD. (RGNT)?

He is identified as a director of REGENTIS BIOMATERIALS LTD. in the Form 3. The filing does not list him as an officer, and no officer title is provided, so his reported equity interests are in his capacity as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ben-Elazar Pini

(Last)

(First)

(Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA

4676652

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, no par value per share	128,666	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	01/23/2035	Common Stock	39,295	$0.01	D
Warrants to purchase ordinary shares	⁽²⁾	12/05/2028	Common Stock	15,831	$5	D

Explanation of Responses:

1. This option grant is fully vested as of this date.

2. The warrants are currently exercisable and have a three year term.

	/s/ Pini Ben-Elazar	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR